CD47 and cancer: A thorough analysis of the correlation between CD47 and other immune checkpoints showed that CD47 expression was positively associated with elevated expression of key immune checkpoints across most cancer types, as well as with tumor mutational burden (TMB) in certain solid cancers such as melanoma, esophageal, and bladder cancer [147].